Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

BUY
$2.33 - $4.0 $2 - $4
1 Added 0.0%
288,169 $718,000
Q1 2022

May 16, 2022

BUY
$3.53 - $7.2 $1.02 Million - $2.07 Million
288,168 New
288,168 $1.38 Million

Others Institutions Holding CMMB

About Chemomab Therapeutics Ltd.


  • Ticker CMMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 11,431,700
  • Market Cap $19.2M
  • Description
  • Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...
More about CMMB
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.